Literature DB >> 5047424

Treatment of rapidly progressing prostatic carcinoma with estracyt.

B Lindberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5047424     DOI： 10.1016/s0022-5347(17)60720-1

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  5 in total

1.  Estracyt in hormone-resistant prostatic carcinoma.

Authors:  Z Szendröi; I Könyves; L Szendi; S Eckhardt; F Hartay
Journal:  Int Urol Nephrol       Date:  1974       Impact factor: 2.370

2.  Effect of estramustine phosphate (Estracyt) on transplantable mouse tumours.

Authors:  M Wakisaka; I Iwasaki; J Shimazaki
Journal:  Urol Res       Date:  1979-12

3.  Treatment of prostatic cancer with Estracyt (estramustine phosphate).

Authors:  F Balogh; L Kisbenedek
Journal:  Int Urol Nephrol       Date:  1975       Impact factor: 2.370

Review 4.  Pharmacokinetics and pharmacodynamics of estramustine phosphate.

Authors:  A T Bergenheim; R Henriksson
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

Review 5.  Estramustine in malignant glioma.

Authors:  A T Bergenheim; R Henriksson; J M Piepmeier; D Yoshida
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.